rc108
mAbexperimentalADC
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Mar 10, 2021 (NCT04617314)
Timeline
Indications
Mechanism of action
- Hepatocyte growth factor receptorBINDING AGENT
MET binding agent
Chemistry & pharmacology
- Payload
- Monomethyl auristatin E
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06962865 | Phase 2 | Jun 30, 2025 | Central South University, RemeGen |
| NCT05821933 | Phase 1/Phase 2 (Phase 2) | Sep 7, 2023 | RemeGen |
| NCT05628857 | Phase 2 | Dec 15, 2022 | RemeGen |
| NCT04617314 | Phase 1 | Mar 10, 2021 | Peking University, RemeGen |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| RemeGen | For profit | 4 | 4 | 2 | 2021 |
| Central South University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1